Travere Therapeutics Inc.

17.95
0.51 (2.92%)
At close: Apr 02, 2025, 3:59 PM
17.43
-2.90%
Pre-market: Apr 03, 2025, 06:10 AM EDT

Travere Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Feb 29, 2012 Feb 28, 2011 Feb 28, 2010 Feb 28, 2009
Revenue 233.18M 145.24M 212.02M 227.49M 198.32M 175.34M 164.25M 154.94M 133.59M 99.89M 28.2M n/a n/a n/a n/a n/a n/a
Cost of Revenue n/a 11.45M 7.59M 6.78M 6.13M 5.23M 5.53M 3.6M 4.55M 2.19M 570.98K n/a n/a n/a n/a n/a n/a
Gross Profit 233.18M 133.79M 204.43M 220.71M 192.19M 170.1M 158.72M 151.33M 129.04M 97.71M 27.63M n/a n/a n/a n/a n/a n/a
Operating Income -320.63M -376.74M -251.56M -139.5M -75.38M -99.81M -80.04M -53.79M -58.21M -50.75M -79.81M -23.97M -30.24M -12.82K n/a n/a -18.27K
Interest Income 17.82M 21.77M 6.28M 1.99M 5M 10.05M 5.5M 700K 3.98M 7.75M 7.43M n/a 21.83K n/a n/a n/a n/a
Pretax Income -320.51M -376.11M -278.17M -179.68M -188.79M -146.45M -101.87M -58.36M -57.58M 105.47M -113.4M -33.75M -30.34M -14.82K n/a n/a -18.27K
Net Income -321.55M -111.4M -278.48M -180.09M -169.43M -146.43M -102.68M -59.73M -47.9M 117.24M -110.94M -33.82M -30.34M -14.82K n/a n/a -18.27K
Selling & General & Admin 264.12M 265.54M 220.21M 149.88M 135.8M 128.95M 103.65M 103.96M 98.02M 79.54M 59.64M 16.89M 30.26M 12.82K n/a n/a 13.43K
Research & Development 217.5M 244.99M 235.78M 210.33M 131.77M 140.96M 123.76M 78.17M 70.85M 50.43M 47.8M 7.08M 662.5K n/a n/a n/a n/a
Other Expenses 75.39M n/a 974K 231K 1.42M -314K -474K 1.11M -264K -296K 570.98M n/a 28.96B n/a n/a n/a n/a
Operating Expenses 557M 521.93M 455.99M 360.21M 267.57M 269.91M 227.41M 182.13M 168.87M 129.97M 107.44M 23.97M 30.26M 12.82K n/a n/a 13.43K
Interest Expense 11.18M 11.33M 11.28M 20.14M 19.05M 18.83M 9.81M 1.19M 34.48M n/a n/a 19.5M 105.92K 2K n/a n/a n/a
Selling & Marketing Expenses n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses 557M 521.98M 463.58M 367M 273.7M 275.15M 232.94M 185.73M 173.42M 132.15M 108.01M 23.97M 30.26M 12.82K n/a n/a 18.27K
Income Tax 120K 223K 313K 409K -19.36M -21K 811K 1.37M -9.68M -11.77M -2.46M 75.78K 2.75K n/a n/a n/a n/a
Shares Outstanding (Basic) 78.89M 74.27M 63.76M 59.83M 47.54M 42.34M 40.42M 38.77M 37M 33.56M 25.04M 14.19M 3.66M 106.68K n/a n/a 95.91M
Shares Outstanding (Diluted) 78.89M 74.27M 63.76M 59.83M 47.54M 42.34M 40.43M 38.77M 38.29M 37.58M 25.06M 14.21M 3.66M 106.68K n/a n/a 95.91M
EPS (Basic) -4.08 -1.5 -4.37 -3.01 -3.56 -3.46 -2.54 -1.54 -1.29 3.49 -4.43 -2.38 -8.29 -0.14 n/a n/a -0.00
EPS (Diluted) -4.08 -1.5 -4.37 -3.01 -3.56 -3.46 -2.54 -1.54 -1.25 3.17 -4.43 -2.38 -8.29 -0.14 n/a n/a -0.00
EBITDA -265.77M -326.25M -299.42M -186.68M -143.95M -107.21M -73.39M -38.67M -38.79M 129.46M -74.11M -34.29M -30.11M -12.82K n/a n/a -18.27K
EBIT -309.33M -364.78M -320.14M -197.2M -169.74M -127.62M -92.06M -53.94M -52.85M 113.22M -79.81M -34.5M -30.24M n/a n/a n/a -13.43K
Depreciation & Amortization 43.55M 38.53M 20.72M 26.62M 25.79M 20.41M 18.67M 17.8M 16.14M 13.39M 5.4M 215.99K 124.89K n/a n/a n/a n/a